Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Revance Therapeutics Inc (RVNC) USD0.001

Sell:$22.54 Buy:$22.57 Change: $0.20 (0.89%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Sell:$22.54
Buy:$22.57
Change: $0.20 (0.89%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Sell:$22.54
Buy:$22.57
Change: $0.20 (0.89%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Contact details

Address:
7555 Gateway Blvd
NEWARK
94560-1152
United States
Telephone:
+1 (510) 7423400
Website:
www.revance.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RVNC
ISIN:
US7613301099
Market cap:
$1.18 billion
Shares in issue:
51.58 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Angus Russell
    Independent Chairman of the Board
  • Mark Foley
    President, Chief Executive Officer, Director
  • Tobin Schilke
    Chief Financial Officer and Principal Financial Officer , Principal Accounting Officer
  • Abhay Joshi
    Chief Operating Officer
  • Caryn McDowell
    Senior Vice President, General Counsel, and Corporate Secretary
  • Taryn Conway
    Vice President of Marketing
  • Dustin Sjuts
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.